Symbols / NTLA Stock $12.45 -5.72% Intellia Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
NTLA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. John M. Leonard M.D.
Exch · Country NGM · United States
Market Cap 1.48B
Enterprise Value 1.11B
Income -412.69M
Sales 67.67M
FCF (ttm) -233.29M
Book/sh 5.77
Cash/sh 3.81
Employees 377
Insider 10d —
IPO May 06, 2016
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -4.28
PEG —
P/S 21.87
P/B 2.16
P/C —
EV/EBITDA -2.58
EV/Sales 16.46
Quick Ratio 4.42
Current Ratio 5.08
Debt/Eq 13.90
LT Debt/Eq —
EPS (ttm) -3.81
EPS next Y -2.91
EPS Growth —
Revenue Growth 78.80%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-02-26
ROA -27.11%
ROE -53.48%
ROIC —
Gross Margin 0.00%
Oper. Margin -4.29%
Profit Margin 0.00%
Shs Outstand 118.93M
Shs Float 111.94M
Insider Own 4.61%
Instit Own 85.67%
Short Float 36.77%
Short Ratio 12.41
Short Interest 38.81M
52W High 28.25
vs 52W High -55.95%
52W Low 6.83
vs 52W Low 82.21%
Beta 1.99
Impl. Vol. 3.13%
Rel Volume 5.70
Avg Volume 4.69M
Volume 26.74M
Target (mean) $26.86
Tgt Median $20.00
Tgt Low $5.00
Tgt High $106.00
# Analysts 21
Recom Buy
Prev Close $13.20
Price $12.45
Change -5.72%
About

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$26.86
Mean price target
2. Current target
$12.45
Latest analyst target
3. DCF / Fair value
$-35.31
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$12.45
Low
$5.00
High
$106.00
Mean
$26.86

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-28 main Canaccord Genuity Buy → Buy $58
2026-04-28 main Goldman Sachs Sell → Sell $9
2026-04-28 main Morgan Stanley Equal-Weight → Equal-Weight $15
2026-04-28 main Citizens Market Outperform → Market Outperform $30
2026-04-27 main Chardan Capital Buy → Buy $30
2026-04-27 main Baird Neutral → Neutral $13
2026-03-04 up Jones Trading Hold → Buy $29
2026-03-03 main Canaccord Genuity Buy → Buy $48
2026-03-03 main Leerink Partners Outperform → Outperform $29
2026-03-03 main RBC Capital Sector Perform → Sector Perform $15
2026-03-03 main Wells Fargo Equal-Weight → Equal-Weight $15
2026-03-03 main Citizens Market Outperform → Market Outperform $28
2026-03-03 main HC Wainwright & Co. Buy → Buy $30
2026-03-02 main Chardan Capital Buy → Buy $27
2026-02-27 main Chardan Capital Buy → Buy $26
2026-01-28 main HC Wainwright & Co. Buy → Buy $25
2025-11-12 down Wolfe Research Outperform → Peer Perform —
2025-11-11 down Jones Trading Buy → Hold —
2025-11-11 down Evercore ISI Group Outperform → In-Line $8
2025-11-10 reit Truist Securities Buy → Buy $14
News
RSS: Latest NTLA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-02 BASTA JAMES EDMUND General Counsel — 1,211 $13.78 $16,688
2026-03-02 CLARK ELIANA Chief Technology Officer — 607 $13.78 $8,364
2026-02-27 LEONARD JOHN M Chief Executive Officer — 156,400 $0.00 $0
2026-02-27 BASTA JAMES EDMUND General Counsel — 46,080 $0.00 $0
2026-02-27 LEBWOHL DAVID Officer — 9,943 $0.00 $0
2026-02-27 DULAC EDWARD J III Chief Financial Officer — 61,280 $0.00 $0
2026-02-27 CLARK ELIANA Chief Technology Officer — 7,353 $0.00 $0
2026-02-27 DUBE MICHAEL P Officer — 17,250 $0.00 $0
2026-02-27 SCHULTES BIRGIT C PH.D. Officer — 39,200 $0.00 $0
2026-01-05 LEONARD JOHN M Chief Executive Officer — 34,146 $9.21 $314,485
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
67.67
+16.92%
57.88
+59.55%
36.27
-30.40%
52.12
Operating Revenue
67.67
+16.92%
57.88
+59.55%
36.27
-30.40%
52.12
Operating Expense
508.66
-14.10%
592.14
+7.36%
551.57
+8.09%
510.29
Research And Development
388.86
-16.61%
466.31
+7.18%
435.07
+3.59%
419.98
Selling General And Administration
119.80
-4.79%
125.83
+8.01%
116.50
+29.00%
90.31
General And Administrative Expense
119.80
-4.79%
125.83
+8.01%
116.50
+29.00%
90.31
Other Gand A
119.80
-4.79%
125.83
+8.01%
116.50
+29.00%
90.31
Total Expenses
508.66
-14.10%
592.14
+7.36%
551.57
+8.09%
510.29
Operating Income
-440.99
+17.46%
-534.26
-3.68%
-515.29
-12.47%
-458.16
Total Operating Income As Reported
-440.99
+17.46%
-534.26
-3.68%
-515.29
-12.47%
-458.16
EBITDA
-425.07
+18.88%
-523.98
-3.49%
-506.31
-12.37%
-450.59
Normalized EBITDA
-424.17
+13.68%
-491.41
+2.92%
-506.21
-15.81%
-437.11
Reconciled Depreciation
15.92
+54.82%
10.29
+14.58%
8.98
+18.54%
7.57
EBIT
-440.99
+17.46%
-534.26
-3.68%
-515.29
-12.47%
-458.16
Total Unusual Items
-0.90
+97.24%
-32.56
-32465.00%
-0.10
+99.26%
-13.48
Total Unusual Items Excluding Goodwill
-0.90
+97.24%
-32.56
-32465.00%
-0.10
+99.26%
-13.48
Special Income Charges
0.00
0.00
+100.00%
-0.10
+99.26%
-13.48
Restructuring And Mergern Acquisition
0.00
0.00
-100.00%
0.10
-99.26%
13.48
Net Income
-412.69
+20.49%
-519.02
-7.86%
-481.19
-1.48%
-474.19
Pretax Income
-412.69
+20.49%
-519.02
-7.86%
-481.19
-1.48%
-474.19
Net Non Operating Interest Income Expense
29.20
-38.93%
47.81
-4.06%
49.83
+483.38%
8.54
Net Interest Income
29.20
-38.93%
47.81
-4.06%
49.83
+483.38%
8.54
Interest Income Non Operating
29.20
-38.93%
47.81
-4.06%
49.83
+483.38%
8.54
Interest Income
29.20
-38.93%
47.81
-4.06%
49.83
+483.38%
8.54
Other Income Expense
-0.90
+97.24%
-32.56
-106.99%
-15.73
+35.95%
-24.56
Gain On Sale Of Security
-0.90
+97.24%
-32.56
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-412.69
+20.49%
-519.02
-7.86%
-481.19
-1.48%
-474.19
Net Income From Continuing Operation Net Minority Interest
-412.69
+20.49%
-519.02
-7.86%
-481.19
-1.48%
-474.19
Net Income From Continuing And Discontinued Operation
-412.69
+20.49%
-519.02
-7.86%
-481.19
-1.48%
-474.19
Net Income Continuous Operations
-412.69
+20.49%
-519.02
-7.86%
-481.19
-1.48%
-474.19
Normalized Income
-411.80
+15.35%
-486.46
-1.11%
-481.09
-4.43%
-460.70
Net Income Common Stockholders
-412.69
+20.49%
-519.02
-7.86%
-481.19
-1.48%
-474.19
Diluted EPS
-3.81
+27.43%
-5.25
+3.14%
-5.42
+12.01%
-6.16
Basic EPS
-3.81
+27.43%
-5.25
+3.14%
-5.42
+12.01%
-6.16
Basic Average Shares
108.38
+9.64%
98.85
+11.35%
88.77
+15.33%
76.97
Diluted Average Shares
108.38
+9.64%
98.85
+11.35%
88.77
+15.33%
76.97
Diluted NI Availto Com Stockholders
-412.69
+20.49%
-519.02
-7.86%
-481.19
-1.48%
-474.19
Earnings From Equity Interest
0.00
0.00
+100.00%
-15.63
-41.10%
-11.08
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
842.13
-29.29%
1,191.02
-8.45%
1,300.98
-14.42%
1,520.11
Current Assets
527.71
-17.53%
639.86
-35.91%
998.33
-17.95%
1,216.80
Cash Cash Equivalents And Short Term Investments
449.88
-25.21%
601.51
-34.06%
912.22
-23.51%
1,192.62
Cash And Cash Equivalents
155.46
-17.82%
189.18
-16.57%
226.75
-56.69%
523.51
Other Short Term Investments
294.42
-28.60%
412.33
-39.85%
685.48
+2.44%
669.12
Receivables
9.47
+11.17%
8.52
-76.64%
36.46
+867.52%
3.77
Accounts Receivable
9.47
+11.17%
8.52
-76.64%
36.46
+867.52%
3.77
Prepaid Assets
—
—
—
—
Other Current Assets
68.36
+129.15%
29.83
-39.92%
49.65
+143.30%
20.41
Total Non Current Assets
314.42
-42.95%
551.15
+82.11%
302.65
-0.22%
303.32
Net PPE
123.63
-49.88%
246.67
+66.52%
148.13
-7.99%
161.00
Gross PPE
182.23
-38.51%
296.36
+57.64%
188.00
-3.19%
194.20
Accumulated Depreciation
-58.61
-17.94%
-49.69
-24.66%
-39.86
-20.07%
-33.20
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
5.21
-5.62%
5.52
+0.04%
5.52
-10.19%
6.14
Other Properties
173.82
-39.57%
287.65
+60.39%
179.34
-3.05%
184.99
Leases
3.20
+0.00%
3.20
+2.07%
3.13
+2.22%
3.07
Investments And Advances
190.79
-37.34%
304.48
+97.06%
154.51
+8.57%
142.32
Long Term Equity Investment
—
0.00
-100.00%
11.77
-63.75%
32.45
Other Investments
35.54
-19.71%
44.26
+3.22%
42.88
+5.81%
40.53
Total Liabilities Net Minority Interest
170.73
-46.49%
319.06
+27.21%
250.81
-11.85%
284.53
Current Liabilities
103.88
-6.29%
110.85
-3.78%
115.21
-8.97%
126.55
Payables And Accrued Expenses
47.04
+2.56%
45.87
-4.15%
47.85
+8.14%
44.25
Payables
20.25
+38.82%
14.59
+95.77%
7.45
+44.59%
5.15
Accounts Payable
20.25
+38.82%
14.59
+95.77%
7.45
+44.59%
5.15
Current Accrued Expenses
26.79
-14.35%
31.28
-22.58%
40.40
+3.34%
39.10
Pensionand Other Post Retirement Benefit Plans Current
23.07
-4.17%
24.07
-9.54%
26.61
+22.21%
21.78
Current Debt And Capital Lease Obligation
26.48
+30.79%
20.25
+8.86%
18.60
+11.47%
16.68
Current Capital Lease Obligation
26.48
+30.79%
20.25
+8.86%
18.60
+11.47%
16.68
Current Deferred Liabilities
7.29
-64.72%
20.66
-6.68%
22.14
-49.50%
43.84
Current Deferred Revenue
7.29
-64.72%
20.66
-6.68%
22.14
-49.50%
43.84
Total Non Current Liabilities Net Minority Interest
66.85
-67.89%
208.21
+53.55%
135.60
-14.16%
157.98
Long Term Debt And Capital Lease Obligation
66.85
-64.81%
189.95
+96.34%
96.75
-15.15%
114.02
Long Term Capital Lease Obligation
66.85
-64.81%
189.95
+96.34%
96.75
-15.15%
114.02
Non Current Deferred Liabilities
0.00
-100.00%
18.26
-53.01%
38.85
+94.93%
19.93
Non Current Deferred Revenue
0.00
-100.00%
18.26
-53.01%
38.85
+94.93%
19.93
Other Non Current Liabilities
—
—
—
24.03
Stockholders Equity
671.39
-23.00%
871.96
-16.97%
1,050.17
-15.01%
1,235.58
Common Stock Equity
671.39
-23.00%
871.96
-16.97%
1,050.17
-15.01%
1,235.58
Capital Stock
0.01
+20.00%
0.01
+11.11%
0.01
+0.00%
0.01
Common Stock
0.01
+20.00%
0.01
+11.11%
0.01
+0.00%
0.01
Share Issued
116.32
+14.00%
102.03
+9.71%
93.00
+6.77%
87.10
Ordinary Shares Number
116.32
+14.00%
102.03
+9.71%
93.00
+6.77%
87.10
Additional Paid In Capital
3,260.44
+6.94%
3,048.74
+12.47%
2,710.80
+12.01%
2,420.22
Retained Earnings
-2,590.09
-18.95%
-2,177.40
-31.30%
-1,658.38
-40.88%
-1,177.19
Gains Losses Not Affecting Retained Earnings
1.03
+70.58%
0.60
+126.79%
-2.26
+69.74%
-7.46
Other Equity Adjustments
1.03
+70.58%
0.60
+126.79%
-2.26
+69.74%
-7.46
Total Equity Gross Minority Interest
671.39
-23.00%
871.96
-16.97%
1,050.17
-15.01%
1,235.58
Total Capitalization
671.39
-23.00%
871.96
-16.97%
1,050.17
-15.01%
1,235.58
Working Capital
423.83
-19.88%
529.01
-40.10%
883.12
-19.00%
1,090.24
Invested Capital
671.39
-23.00%
871.96
-16.97%
1,050.17
-15.01%
1,235.58
Total Debt
93.33
-55.60%
210.20
+82.23%
115.35
-11.75%
130.70
Capital Lease Obligations
93.33
-55.60%
210.20
+82.23%
115.35
-11.75%
130.70
Net Tangible Assets
671.39
-23.00%
871.96
-16.97%
1,050.17
-15.01%
1,235.58
Tangible Book Value
671.39
-23.00%
871.96
-16.97%
1,050.17
-15.01%
1,235.58
Available For Sale Securities
155.25
-40.34%
260.21
+160.57%
99.86
+44.02%
69.34
Investmentin Financial Assets
155.25
-40.34%
260.21
+160.57%
99.86
+44.02%
69.34
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-394.74
-13.14%
-348.88
+11.47%
-394.09
-18.24%
-333.29
Cash Flow From Continuing Operating Activities
-394.74
-13.14%
-348.88
+11.47%
-394.09
-18.24%
-333.29
Net Income From Continuing Operations
-412.69
+20.49%
-519.02
-7.86%
-481.19
-1.48%
-474.19
Depreciation Amortization Depletion
15.92
+54.82%
10.29
+14.58%
8.98
+18.54%
7.57
Depreciation
15.92
+54.82%
10.29
+14.58%
8.98
—
Depreciation And Amortization
15.92
+54.82%
10.29
+14.58%
8.98
+18.54%
7.57
Other Non Cash Items
—
-20.97
-411.82%
6.72
-91.69%
80.88
Stock Based Compensation
80.22
-48.00%
154.27
+15.09%
134.05
+46.66%
91.40
Operating Gains Losses
0.53
+793.42%
-0.08
-100.48%
15.71
+43.86%
10.92
Unrealized Gain Loss On Investment Securities
0.90
-97.24%
32.56
0.00
0.00
Gain Loss On Sale Of PPE
0.53
+793.42%
-0.08
-205.56%
0.07
+144.44%
-0.16
Change In Working Capital
-73.75
-720.91%
11.88
+122.65%
-52.45
+2.64%
-53.87
Change In Receivables
-0.95
-103.40%
27.94
+185.47%
-32.69
-1781.87%
-1.74
Changes In Account Receivables
-0.95
-103.40%
27.94
+185.47%
-32.69
-1781.87%
-1.74
Change In Prepaid Assets
-26.35
-608.33%
5.18
+119.08%
-27.17
-1157.78%
-2.16
Change In Payables And Accrued Expense
0.72
+119.98%
-3.58
-141.93%
8.55
-24.64%
11.34
Change In Accrued Expense
-5.27
+49.23%
-10.38
-272.36%
6.02
-62.17%
15.92
Change In Payable
5.99
-11.96%
6.80
+169.63%
2.52
+155.02%
-4.58
Change In Account Payable
5.99
-11.96%
6.80
+169.63%
2.52
+155.02%
-4.58
Change In Other Working Capital
-28.11
-27.34%
-22.08
-694.67%
-2.78
+95.62%
-63.46
Change In Other Current Assets
35.90
+60.38%
22.38
+22.28%
18.30
+52.15%
12.03
Change In Other Current Liabilities
-54.95
-205.81%
-17.97
-7.81%
-16.67
-68.67%
-9.88
Investing Cash Flow
228.03
+81.60%
125.57
+500.57%
-31.35
-119.55%
160.31
Cash Flow From Continuing Investing Activities
228.03
+81.60%
125.57
+500.57%
-31.35
-119.55%
160.31
Net PPE Purchase And Sale
-1.13
+80.46%
-5.78
+58.68%
-13.98
-4.30%
-13.41
Purchase Of PPE
-1.13
+80.46%
-5.78
+58.68%
-13.98
-3.15%
-13.56
Sale Of PPE
—
0.00
0.00
-100.00%
0.15
Capital Expenditure
-1.13
+80.46%
-5.78
+58.68%
-13.98
+76.05%
-58.39
Net Investment Purchase And Sale
229.16
+74.47%
131.34
+856.51%
-17.36
-107.94%
218.55
Purchase Of Investment
-322.51
+65.53%
-935.57
-3.44%
-904.46
-110.82%
-429.03
Sale Of Investment
551.67
-48.29%
1,066.92
+20.27%
887.10
+36.99%
647.58
Net Business Purchase And Sale
—
—
0.00
0.00
Purchase Of Business
—
—
0.00
0.00
Net Intangibles Purchase And Sale
—
0.00
0.00
+100.00%
-44.83
Purchase Of Intangibles
—
0.00
0.00
+100.00%
-44.83
Financing Cash Flow
131.49
-29.21%
185.75
+42.53%
130.32
-77.64%
582.96
Cash Flow From Continuing Financing Activities
131.49
-29.21%
185.75
+42.53%
130.32
-77.64%
582.96
Net Common Stock Issuance
128.18
-27.54%
176.90
+47.67%
119.80
-78.83%
565.79
Proceeds From Stock Option Exercised
3.31
-62.58%
8.85
-15.96%
10.53
-38.67%
17.17
Changes In Cash
-35.22
+6.25%
-37.57
+87.27%
-295.11
-171.98%
409.98
Beginning Cash Position
202.79
-15.63%
240.35
-55.11%
535.46
+326.71%
125.49
End Cash Position
167.57
-17.37%
202.79
-15.63%
240.35
-55.11%
535.46
Free Cash Flow
-395.87
-11.62%
-354.66
+13.09%
-408.07
-4.19%
-391.68
Amortization Of Securities
-5.86
+67.12%
-17.82
+31.20%
-25.90
-746.94%
4.00
Common Stock Issuance
128.18
-27.54%
176.90
+47.67%
119.80
-78.83%
565.79
Earnings Losses From Equity Investments
0.00
0.00
-100.00%
15.63
+41.10%
11.08
Issuance Of Capital Stock
128.18
-27.54%
176.90
+47.67%
119.80
-78.83%
565.79
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category